

Blurring the Lines: Pain and Demyelinating Conditions

Charles E. Argoff, M.D.

Title & Affiliation

Charles E. Argoff, M.D.

Professor of Neurology

Albany Medical College

Vice Chair, Department of Neurology

Director, Pain Management Fellowship

Director, Comprehensive Pain Management

Center

Albany Medical Center

Albany, NY



Disclosures

Charles E. Argoff, MD

Consulting Fee (e.g., Advisory Board): BDSI, Vertex, Teva, Amgen, Lilly, Neumentum, Collegium, Lundbeck, Gruenenthal, Redhill Pharma Contracted Research : Teva, Lilly, Amgen, Abbvie Speakers' Bureau: Abbvie, Amgen, Lilly, Teva, Lundbeck, Biohaven, Red Hill Pharma, Gruenenthal



Learning Objectives

- Describe how commonly people diagnosed with multiple sclerosis experience chronic pain
- List painful conditions associated with multiple sclerosis and other demyelinating disorders
- Describe available treatments for pain associated with multiple sclerosis



Pre-test question #1

- A 30 year old female with a 10 year personal as well as family history of migraine headaches presents to her primary care provider for an annual health assessment. She describes having episodes of severe, sudden shock-like pain over the right mandible lasting seconds to minutes. She often cannot brush her teeth without pain. Her dentist has evaluated her recently and no dental etiology has been determined. Here PCP notes several trigger zones over the affected area when examining her. What is the most appropriate step for this patient?
- A. PCP should advise the patient that her complaints and findings are consistent with migraine and discuss new treatments for her headaches.
- B. PCP should advise the patient that her complaints are consistent with trigeminal neuralgia and she should be referred to a Neurosurgeon for consideration of microvascular decompression surgery.
- C. PCP should advise the patient that her complaints are consistent with trigemeinal neuralgia and she is advised to undergo a MRI Brain with and without contrast.
- D. PCP should advise the patient that her complaints are consistent with temporomandibular joint dysfunction and she is advised to see a TMJ specialist.

Painweek.

Pre-test question #2

 T/F: 20% of people diagnosed with multiple sclerosis experience associated chronic pain.



Pre-test question #3

T/F: A recent study suggests that most pain associated with multiple sclerosis is neuropathic pain.



Examples of Demyelinating Disorders Affecting the CNS

- Multiple sclerosis: potentially disabling disease of the brain and spinal cord in which the immune system attacks the myelin of the CNS
- Transverse Myelitis: acute inflammation of the spinal cord, most commonly in the thoracic region. Causes include multiple sclerosis, neuromyelits optica, directed related to infection or post-infectious, drug related or associated with vasculitis
- Balo's concentric sclerosis: rare disorder (some believe variant of multiple sclerosis), associated with a concentric circular pattern of sclerosis
- Neuromyelitis optica (NMO/Devic's Disease): an auto-immune, inflammatory condition associated with optic nerve and spinal cord attacks

Pain in Multiple Sclerosis (and other demyelinating conditions)

- Multiple sclerosis: demyelinating disorder affecting the central nervous system in which the immune system attaches the myelin sheath of the CNS
- The prevalence of pain in multiple sclerosis (MS) ranges from 50-86% (pooled prevalence from 17 studies is 62%)
- Pain, fatigue and depression are frequently noted within the first year of MS diagnosis
- Neuropathic pain, specifically trigeminal neuralgia has been noted to be an initial symptom of MS when a young person presents with this condition

Murphy KL et al. Neuropathic Pain in MS-Current Therapeutic Intervention and Future Treatment Perspectives, In: Multiple Sclerosis Perspectives in Treatment and Pathogenesis, Zagon I and Mclaughlin P, eds. Codon Publications, Brisbane: 2017:53-69. Valentine TR, et al. Prevalence, co-occurrence and trajectories of pain, fatigue, depression and anxiety in the year following multiple sclerosis diagnosis. MS Journal, June 2021 PMID:34132141, Foley PL et al. Prevalence and natural history of pain in adults in multiple sclerosis: Systematic review and meta-analysis. Pain 154(2013):632-642.



Painful Conditions in MS

- Neuropathic pain: prevalence in MS has been reported to be as high as 86%
- Extremity pain and TN are common presentations
- Neuropathic pain in a patient with MS may signify a more severe disease course based upon number of lesions reported in such patients
- Neuropathic pain in MS is associated with a negative effect on QOL
- Lhrmitte's sign occurs in as many as 40% of patients with MS
- Glossopharyngeal neuralgia- rare in MS
- Spasticity and spasms frequently noted in MS patients can be painful

Urits I, et al. Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review. Current Pain and Headache Reports (2019) 23:59, PMID 31342

Painweek.

Characterizing Chronic Pain Phenotypes in MS: a Nationwide Survey Study

- Noting that pain heterogeneity may be associated with poor treatment outcomes, this study was designed to characterize pain phenotypes in people with MS
- A national web-based survey was used to collect data
- Measures included painDETECT (neuropathic pain), nociplastic pain (Fibromyalgia Survey Criteria), chronic overlapping conditions, pain medication use and pain relief
- 842 MS patients with chronic pain and MS
- 41% nociceptive pain, 27% mixed neuropathic/nociplastic pain, 23% nociplastic pain, 9% neuropathic pain
- Findings suggested need for multidimensional assessment of pain- improved characterization could help improve therapeutic approaches

Kratz AL, et al. Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study. Pain 162(2021):1426-1433



Neuromyelitis Optica Spectrum Disorder

- Characterized by severe immune mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord as well as the brain and brainstem
- Symptoms include visual loss, paralysis and episodes of hiccups, nausea and vomiting
- Diagnostic tests include a blood test: aquaporin-4 IgG antibodies highly specific
- No specific medical therapies have been noted for the central neuropathic pain that is frequently associate with this condition
- A recent study notes that scrambler therapy (a type of TENS therapy)may improve pain in NMO

Mealy M, et al. Scrmbler therapy improves pain in neuromyelitis optica. Neurology 2020;94:e1900-e1907.



Treating MS Related Pain is Not Equivalent to Treatingan Infection Caused by a Known Pathogen


		ME) 07/15/10 1733 (IN LAB TIME)
-S	BACTERIAL CULTURE	FINAL ON 07/21/10 1517
-	SPECIMEN TYPE	WOUND
_	SOURCE-BODY SITE	GROIN
-	ORGANISM 1	BETA STREPTOCOCCUS GROUP B
-	QUANTITATION	MANY
-	ORGANISM 2	STAPHYLOCOCCUS LUGDUNENSIS
-	QUANTITATION	MODERATE
-	SENSITIVITY SET-UP DATE:	07/20/10
-	ORGANISM 3	CORYNEBACTERIUM SPECIES
-	QUANTITATION	MODERATE
-	MIC in mcg/mL	COST/ ORG 2
-	*USUAL ADULT IV DOSAGE	DAY*
-	CLINDAMYCIN	\$ 24 <=0.5 S
-	DOXYCYCLINE	\$ 32 <=1 S
-	ERYTHROMYCIN	\$ 35 <=0.5 S
-	OXACILLIN	\$ 70 0.5 S
-	PENICILLIN	\$ 38 0.06 S
-	RIFAMPIN	\$ 33 <=0.5 S
-	VANCOMYCIN	\$ 21 1 S
-	Erythromycin :	Susceptible STAPHYLOCOCCUS LUGDUNENS

Erythromycin Susceptible STAPHYLOCOCCUS LUGDUNENSIS are susceptible to azithromycin and clarithromycin.

Oxacillin-susceptible staphylococci are susceptible to cefazolin, cephalexin and ceftriaxone.



Gabapentin in the Treatment of **Painful Diabetic Neuropathy***



Adapted from Backonja M, et al. JAMA. 1998;280(21):1831-1836.

Evidence Based Medicine

Evidence-based medicine (EBM) has been defined as "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients" ackett, D. Evidence-based Medicine - What it is and what it isn't. BMJ 1996; 312:71-72
 Evidence-based medicine: The judicious use of the best current available scientific research in making decisions about the care of patients. Evidence-based medicine (EBM) is intended to integrate clinical expertise with the research evidence and patient value

http://www.medterms.com/script/main/art.asp?articlekey=33300



Clinical Syndromes and Anticonvulsant Use

- Migraine topiramate, divalproex sodium
- Postherpetic neuralgia
 - -gabapentin
 - pregabalin
- Diabetic neuropathy
 - carbamazepine
 - phenytoin
 - -gabapentin
 - lamotrigine
 - -lacosamide
 - pregabalin

PainWeek.

- Spinal cord injury- pregabalin
- HIV-associated neuropathy
 - -lamotrigine
- Trigeminal neuralgia
 - carbamazepine
 - lamotrigine
 - oxcarbazepine
- Fibromyalgia
- pregabalin
- Central post-stroke pain
 - lamotrigine

Current pharmacotherapy considerations

- Acetaminophen
- NSAIDs
- TCA or SNRI antidepressant agents
- Na⁺ blocker anticonvulsants
- Ca²⁺ modulating anticonvulsants
- Tramadol
- Opioids
- TRPV1 topical agents
- Local anesthetic topical agents
- Botulinum toxin

NGGK

Bannister K, et al. Neuropathic Pain" Mechanism-Based Therapeutics Annu Rev Pharmacol Toxicol 2020.60:257-274.

TCA Antidepressant Agents

- Numerous studies have demonstrated the benefit of TCA agents (amitriptyline, nortriptyline) for NeP
- •NNT ranges from 3-4.4
- The evidence is rated as strong and these are considered first line agents
- Common side effects include somnolence, constipation, dry mouth



SNRI Antidepressant Agents

- Multiple studies demonstrate the analgesic benefit in NeP
- NNT ranges from 5.2-8.4
- The evidence is rated as strong
- Nausea is a common side effect especially for duloxetine



Ca²⁺ modulating anticonvulsants

- Multiple studies demonstrate the analgesic benefit of these agents for NeP
- Pregabalin is considered a first line agent with NNT ranging from 6.5-9.4
- Gabapentin is considered a first line agent with NNT ranging from 5.9-9.1
- Side effects include somnolence, dizziness and weight gain
- Recent labeling changes point out the enhanced risk of respiratory depression when used with opioids



Opioids

- Opioids have demonstrated benefit in multiple NeP conditions
- NNT ranges from 3.4-5.8
- The evidence for their benefit is considered weak and opioids are considered third line agents
- Side effects include constipation, nausea, emesis, pruritus



Tramadol

- The evidence for the use of tramadol in NeP is weak
- NNT ranges from 3.6-6.7
- Tramadol is considered a second line agent for NeP
- Tramadol has tricyclic like acitivity and its metabolite has weak mu receptor activity
- Side effects include nausea, constipation, dizziness and dry mouth



Topical capsaicin

- The 8% capsaicin patch may be considered for peripheral NeP
- It is now FDA approved for PHN and PDN
- The NNT ranges from 7.4-18.8 BUT recent studies suggest patients who do not benefit from initial application may benefit from repeated application
- Side effects include local pain and erythema



Bouhassira D, Attal N, Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? Pain 159 (2018):576-582

Botulinum Toxin

- Multiple animal studies and/or evaluations of known pain models in healthy subjects, have demonstrated that botulinum toxin (specifically onabotulinum toxin A) may result in analgesia independent of its effect on muscle
- Multiple single center RTC have evaluated the long term efficacy of subcutaneous or intradermal injections (50-200 units) in PHN, painful diabetic neuropathy of neuropathic pain following traumatic nerve injury
- A multicenter double-blind RTC has evaluated the effect of 2 subcutaneous treatments of onabotulinum toxin A, 12 weeks apart in 66 patients with PHN. Posttraumatic neuropathy or painful polyneuropathy- treatment resulted in improved average pain intensity compared to placebo and the second injection provided greater benefit- allodynia and paroxysmal pain was specifically helped
- The NNT ranges from 1.5-2.4
- Adverse events include local pain

Painweek.

Botulinum Toxin/Capsaicin

- Botulinum toxin: known benefit in chronic migraine/DPN
- In migraine, the effect is believed to be via a block of peripheral CGRP release
- However, no effect on peripheral CGRP levels has been seen in NeP
- Capsaicin is a TRPV1 agonist- application of the high concentration patch leads to local depletion of TRPV-1 and chemical denervation leading to reduced superficial nociceptive afferents in the skin- for several months after the application

Bannister K, et al. Neuropathic Pain" Mechanism-Based Therapeutics Annu Rev Pharmacol Toxicol 2020.60:257-274



FDA-APPROVED INTRATHECAL ANALGESICS with different mechanisms

Morphine

- µ-Opioid receptor agonist
- Most serious AE is respiratory depression
 - Risk increased with other agents that depress the CNS
 - (eg, benzodiazepines)

Ziconotide

- N-type Ca²⁺ channel blocker
- Most serious AEs are neurocognitive
 - -eg, confusion, dizziness, hallucinations
 - Urinary retention also can lead to treatment discontinuation

AE, adverse event; CNS, central nervous system. Coffey RJ, et al. *Anesthesiology*. 2009;111(4):881-891; Deer TR, et al. *Neuromodulation*. 2012;15(5):436-466; Prager JT, et al. *Neuromodulation*. 2014;17(4):354-372; Webster LR, et al. *J Pain Symptom Manage*. 2009;37(3):363-372.



OVERVIEW OF SYSTEMIC VS INTRATHECAL THERAPY

Systemic drug delivery

- Drug distributed via bloodstream
- Drug interacts with receptors throughout the body
- Oral dosing produces peaks and troughs in plasma levels
- Relatively high daily dosages
- High systemic side effect risk and drug-elimination load

Concerns about adherence, abuse, and diversion

CSF, cerebrospinal fluid.

Bagnall D. Phys Med Rehabil Clin N Am. 2010;21(4):851-858; Deer TR, et al. Pain Physician. 2010;13(3):E175-E213; Hayek SM, et al. Pain Physician. 2011;14(3):219-248; Onofrio BM, et al. Mayo Clin Proc. 1981;56(8)516-520; Prager J, et al. Neuromodulation. 2014;17(4):354-372.



Intrathecal drug delivery

- Implantable pump sends drug via catheter to intrathecal CSF
- Drug targeted to spinal receptors
- Steady-state around-the-clock dosing can be achieved
- Relatively low daily dosages
- Reduced systemic side effects and low drug-elimination load
- Potential for better adherence and less diversion

NEW PACC RECOMMENDATIONS

Mariel Ma	The (PAC Deli Mitti Timot Tim J
Anjum Bux, MD, FIR, MD, PhD, EDRA ⁺⁺ ; Michael M, Barger, Daniel M, Doleys, Huse	Timot
Dennis c Jacobs, PhD , 555, Mark S, Wallace, Multir Diwan, MD	Tim J. Mark
Marilyn 5, Juden Doby, Minter M. (1995), Marine M. (1997), Sudari Doby, Sudari Doby	Joshu
Richard Rauck, MD MD 1999; Helena M. Gazesses.	
Steven M. Falowski, Hither Michael Leong, McDowell II, MD	Davi
Richard Rauck, MD ¹¹ , MD ¹⁴ st, Helena M. Gazeira, e.c. Steven M. Falowski, MD ¹⁴ st, Michael Leong, MD ¹⁵⁵⁹⁵ , MD ¹⁵⁵⁹⁵ , Philip Kim, MD ¹¹ tt ¹ +tt ¹ +tt ¹ , Michael Leong, MD ¹⁵⁵⁹⁵ , Robert M. Levy, MD, PhD ¹⁵⁵⁹⁵ , Gladstone McDowell II, MD ¹¹ Robert M. Levy, MD, PhD ¹⁴⁵⁰⁵ , Gladstone McDowell M, MD ¹¹ Robert M. Levy, MD, PhD ¹⁴⁵⁰⁵ , Gladstone McDowell M, MD ¹¹ Robert M. Levy, MD, PhD ¹⁴⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹⁵⁰⁵ , Gladstone M, MD ¹¹ Robert M, Levy, MD, PhD ¹¹ Robert M, PhD ¹¹ Rob	Brian
Roberts MD access christophe Perruction and titter	In

Kobert M. Levy, M., MDHHHH, Ramana Naidu, MD^{#####}; Porter M.Roberts, MDHHHH, Ramana Naidu, MD^{#####}; Samir Narouze, MD, PhD⁵⁵⁵⁵⁵⁵; Christophe Perruchoud, MD^{#####}; Steven M. Rosen, MD^{***###}; William S. Rosenberg, MDHHHHH; Michael Saulino, MD, PhD^{######}; Peter Staats, MD⁵⁵⁵⁵⁵⁵⁵⁹⁵⁹⁴⁹⁴⁹⁴; Lisa J. Stearns, MD^{*******}; Dean Willis, MD^{HHHHH}; Elliot Krames, MD^{######}; Marcé Huntonn, MD⁵⁵⁵⁵⁵⁵⁵; Nagy Mekhail, MD, PhD^{######} Lisa J. Stearns, MD*******; Dean Willis, MD******; Elliot F Marc Huntoon, MD⁵⁵⁵⁵⁵⁵⁵; Nagy Mekhail, MD, PhD^{egeggggg} safety-based philosophy is used to determine an algorithmic process to inized a group of experts to evaluate evidence and create a Pdyanalge

<text><text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text></text>	nai c i i i	when a patient-centr	it, said a group of experts to evaluate	
<text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text>	to a Baio trea	tment is best performed whation Society has o	organized a group	us PACC publication of
<text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text>	Introduction: Panto	e International Neuromodul	d innovations emerging since the pre-	contributed additional
<text><text><text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text></text></text>	guide care. Since and conference	e (PACC) to guide practice and to address the del	ficiencies and internet November 22, 2015 and address	indations for intrathecan
<text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text>	sic Consensus Convent	PACC update was designed to a service la	anuary 15, 2007 and levels and degrees of recommenders, Alg	arithms were developed
<text><text><text><text><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></list-item></text></text></text></text>	Methods: The current	ture search identified publications convened to	determine evolution as strong moderate or water	nd noncancer pain, which
 Makengen Tilsensendeng and Aller medication and an excise processing and excise procesing and excise processing and excise processing and excise pr	2012. An extensive litera	eviewing the literature, the parts development,	which was reatients with cancer, terminal	
 By Annow an endocation for each of the second and action of the second action of	relevant sources. Artes	erved as the basis for consentive and neuropat	thic pain the pain	inte safe and efficacious
 Builtonization of afficing PML. Builtonization of afficing PML of af	therapy. This meeting	ion choices to treat nocice part	of intrathecal drug delivery to pro-	points emerged from the
 Bartian Tta PACC has developed an algoing engenese, was used to its of a grant consideration. Bartian Tta PACC has developed an algoing engenese, was used to its of a grant consideration. Bartian Tta PACC has developed an algoing engenese, was used to its of a grant consideration. Bartian Tta PACC has developed an algoing engenese and the sense can easily have algoing engenese and the sense of the sense for easily of the sense can easily algoing engenese and the sense can easily have algoing engenese and the sense of t	for intrathecal model of diffu	se pain.	weral aspects of mevidence. Thirty-one conservation	
previous constraints:	either localized of care	developed an algorithmic processe, was t	used to Nil gaps in contract	
previous constraints:	Results: The PACC	Consensus opinion, based on experi	the use of intrathecal drug de	avery-
public description and guidance near energy of the second	evidence-based care.		to improve care with the other	a DecTDectR
Address summigradement to Throuty JL, Due, MD, President and CBU, Hor-Construction • Conser Som Noted, Charler Son, WY, LINE, • Conservation from Noted, Charler Son, WK, Charler Son, WK, Charler Son, Harder Son, Barrer MD, Wattersberg, MK, WK, • The Joint Conservation from Note Regional Medical Conservation (Neuronal Networks Neuronal Networks Neuronal Neuronal Networks Neuronal Ne	panel considerations.	and guidance have been established	100 Chat	leston, WV, USA. Email: Doct Doct
Address summigradement to Throuty JL, Due, MD, President and CBU, Hor-Construction • Conser Som Noted, Charler Son, WY, LINE, • Conservation from Noted, Charler Son, WK, Charler Son, WK, Charler Son, Harder Son, Barrer MD, Wattersberg, MK, WK, • The Joint Conservation from Note Regional Medical Conservation (Neuronal Networks Neuronal Networks Neuronal Neuronal Networks Neuronal Ne	Condusion: New a	gonthins and g	a to patied Inc. 400 Court Street, Ste Tou, Cha	
Control for Pann and Charles WU, USK Control Fann Receiver, Stank Back, CAUX Control Fann Receiver, USK (CAUX) Control Fann Recei		ident and CEO, The Ce	enter for Pain Network	
Control for Pann and Charles WU, USK Control Fann Receiver, Stank Back, CAUX Control Fann Receiver, USK (CAUX) Control Fann Recei		Timothy R. Deer, MD, President and		
Control for Pann and Charles WU, USK Control Fann Receiver, Stank Back, CAUX Control Fann Receiver, USK (CAUX) Control Fann Recei	Address correspondence to:			
 Samith Jamin Rome Useling Ju. Samith Control Rightson. and OxfW Usersity Inscience. Anachista and Pan Namy Hospita, Maldabologi Roman, Galago and OxfW Usersity Inscience. Namitha and Pan Namy Hospita, Maldabologi Roman, Warrisk, Samitha Samitha, Battonet, Mo, Uski, Samitha Samitha, Sam				
 Samith Jamin Rome Useling Ju. Samith Control Rightson. and OxfW Usersity Inscience. Anachista and Pan Namy Hospita, Maldabologi Roman, Galago and OxfW Usersity Inscience. Namitha and Pan Namy Hospita, Maldabologi Roman, Warrisk, Samitha Samitha, Battonet, Mo, Uski, Samitha Samitha, Sam	for Pain Relief, Chu	afeston WV, USA	Densille, KY, USA:	
 All Loren Cox University Ploy stand General University school of Medicine, university school of Medicine Cox Medicine, John Regulari University school of Medicine, Universit	* Center for * Cummit Pain Alliance, Sat	sta Rosa, Cleveland, OH, USA:	Medical Center, Danie Hospital, Lausanne, Switzenanne	
 All Loren Cox University Ploy stand General University school of Medicine, university school of Medicine Cox Medicine, John Regulari University school of Medicine, Universit	* Case Western Reserve Un	pain Management, Ephraim McCosptial, Morges, a	and CHUV Gritter y	
 All Loren Cox University Ploy stand General University school of Medicine, university school of Medicine Cox Medicine, John Regulari University school of Medicine, Universit	⁵ Anesthesia and Chronic	anagement Department, Eric	NO ISA:	
the set is show of Macillow Realization, Joint Maparia Similary Set Ware Macillow and Critical Case Marine Marine Marine Pain Services, Learington, RY, USA, Ware Network Configure Macillow UK-Marine Pain Services, Learington, RY, USA, Ware Macillow Context, Los Acades, La Marine Pain Services, Learington, RY, USA, Ware Macillow Context, Los Acades, La Marine, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology and Pharmacology, University of California, San Diego, CA, USA, Warehenkology, University of California, San Diego, CA, USA, Warehenkology, UNIV, San Diego, San Diego, CA, USA, Warehenkology, San Diego, San Diego, San Diego, CA, USA, Warehenkology, San Diego, San	1 Anaesthesia and Palitie	rsity Hospital, Middles Universitario, Valencia, Sp	hool of Medicine, Baltimore, MD, 400	
Blowering of Kenselv Cours AL USA. Host Course and AL USA. Course and AL USA				
Blowering of Kenselv Cours AL USA. Host Course and AL USA. Course and AL USA	The America Sology and Co	Itical Care Miami, FL, USA;	el, Lexington, Kr, Olik	
Dotype: Dotype: A file Medicine Centrel, US You Provide California, San Corp. 11 California Pain Medicine Centrel, US You Provide California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of Califor				
Dotype: Dotype: A file Medicine Centrel, US You Provide California, San Corp. 11 California Pain Medicine Centrel, US You Provide California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 11 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of California, San Corp. 12 Medicine Idoog and Pharmacology, University of Califor	# University of Kentucki	wham ALUSA: In CAUSA:	CALIER	
Anesthesiakogy 201 C 2017 International Neuromodulation Society	++ Doleys Clinic, Barrier	cine Center, Los Angeles, Col California, San Dieg	0, 0, 0, 0, 1	Neuromodulation 2017; -< -
© 2017 International	ttt California Part and	Pharmacology, University	(- date	Neuronne
www.neuromodulationjournat.com © 2017 Interaction	+++ Aneines acogy		terestional Neuromodulation Society	
www.netromodulationjournal.com		© 2017 in	TEL LINCO	
WWW.JB.G.	romodulati	onjournal.com		
	WWW THE GOLD			


		Ac cepted: December 7, 2016	
Received: October 27, 2016	Revised: November 12579		6
in a subley com	DOF 101111/1811	-	us Conference
(un	analae	sic Consens	for Intrathecal
The PO	yanaige	adations	for intrattice
	Decom	menuations	wing Satety

for Intrathecal Drug ivery: Guidance for Improving Safety and

othy R. Deer, MD*; Jason E. Pope, MD[†]; Salim M. Hayek, MD, PhD[‡]; I. Lamer, MD⁹; Ilir Elias Veizi, MD[†]; Michael Erdek, MD^{**}; S. Welker Marth Levis Conten Dr. MRA**, Debuty 47 J. Lamer, MU-; III Elias Velzi, MU-; Michael Erdek, MU-;; K S. Wallace, MD^{+;} Jay S. Grider, PhD, MBA^{+;}; Robert M. Levy, MD, PhD⁵⁵ UN Percer ADD⁴; Jay S. Grider, M. Decer M. Decer M. Levy, MD, PhD⁵⁵ N. S. Wallace, MD. 17 Jay S. Gruer, Filo, MD. 7, NOBEL M. LEVY, MD, FIL 100 Prager, MD⁴⁸, Steven M. Rosen, MD⁴⁴⁴, Michael Saulino, MD, PhD¹¹¹, 11 Value, PhD⁴⁴, Ioco A. Do Andrée MD, PhD, EIDD, EDD, A555. shua Prager, MD^{NI}; Steven M. Rosen, MD^{*++}; Michael Saulino, MD, PhD¹ ny L. Yaksh, PhD⁺⁺⁺; Jose A. De Andrés, MD, PhD, FIPP, EDRA^{\$55}; rid Abejon Gonzalez, MD^{\$16}; Jan Vesper, MD^{*+++}; Stefan Schu, MD⁺⁺⁺⁺; In Simpson, MD⁺⁺⁺⁺; Nagy Mekhail, MD, PhD⁵⁵⁵⁵ Introduction: Intrahecal therapy is an important part of the pain treatment algorithm for duranic disease states. The use of this

INFORMETION: Intramical Unitary to an important part on the pain themetion adjustment adjustment adjustment and information and the assessment and mitigation. In this provide interaction adjustment adjust option is a value treatment strategy, but it is innerent tor pain physicare to uncersarily no as assess manuscript, we explore evidence and mitigating strategies to improve safety with instathed therapy. Methods A robust leterature earch was performed overing january 2011 to October 9, 2016, in PubMed, Enbase, MEDURE MRINOSE: A robust leararule search was performed covering January 2011 to Uctoper 9, 2016, in Prusteed, Embase, NacULAE Biologi Central, Google Scholar, Currett Contents Connect, and International Phermaceutical Abusics. The information was Biomed Central, Google Scholar, Current Contents Connect, and International Pharmaceutroal Asstracts. The information was cross-referenced and compiled for evidence, analysis, and consensus meleor, with the intent to offer weighted recommendations and Understale Selections and any one spread and an any other selection of the second selection to improve care and reduce Reads: The Polyanalgence Conversion Conference has made select a best profile recommendations to improve care and reduce the selection of the second selection of the selection of the second second selection of the second selection of the second secon Mexate: The Poyanages: Conserva Conserva has made severa one practice recommendations to encouve care and escua modulity and modulity associated with intrathecial therapy through all phases of management. The Unded States Prevention Serincruosty and mortanty associated with interanetial therapy strough an phases or management, ine uneed vice Task Force evidence level and consensus strength assessments are offened for each recommendation. No real rare entence even and commons avergin also arena are overea to each recommendation. Conclusion intraducal therapy is a viable and relatively sele option for the treatment of ances and nonancerelated pairs. Concession: intramecal merphy is a viable and relatively sate option for the treatment of cancer- and noncancer-related pain. Confinited related and expert option are required to improve our current pharmacolinetic and pharmacodynamic model of Intrahleci alone as this will understands inverses related and afficiency. Continued research and expert option are required to improve our current , Intrathecal drug delivery, as this will undoubtedly improve safety and efficacy. , 400 Court Street, Ste 100, Chadeston, WV, USA. Email: DocTDee

- 1
- 1
1
- 1
- 1
- 1
- 1
- 1
1
- 1
1
- The M
A CHAST
-
-
20 155
er Elas V
-



com	SA: stern Reserve University, Cleveland, OH, USA: SA:	
for Pain Reliet, Charleston, WV, O.	dem Reserve University, Carvester	
Hospitals Case Medical Center, Case Medical Center, Case Medical Center, Case Medical Center, Case Microsoft Case Medical Center, Case Microsoft Case Microsoft Case Medical Center, Case Microsoft Case Medical Center, Case Medical Center, Case Microsoft Case Medical Center, Case Medical Center, Case Microsoft Case Medical Center, Case Medical C	sk:	
Summit Pain Alliance, Santa Rosa, C.K. Summit Pain Alliance, Santa Rosa, C.K. Mayo Clinic, Rochester, MN, USA: Mayo Clinic, Rochester, MN, USA: Virginia Commonwealth University Spin Virginia Commonwealth University Spin	ve Center, Richmond, VA, USA; y of Kentucky College of Medicine, Lexington, KY, USA; ; Challfont, PA, USA; Talk, OH, USA;	
Summer Clinic Rochester, MN, USA	e Center, Richmond, Medicine, Lexington, Ki, Olar	
Mayo Cammonwealth University	y of Kentucky College of the	
+ LIK HealthCare Pain Services, Constitute,	Chalfront, PA, USA	
Virginia Commonwealth of the WKHealthCare Pain Services, University WKHealthCare Pain & Spine Institute, Delaware Valley Pain & Spine Institute, Delaware Va	Falls, OH, USA	
UKHealthCare Pain & Spine Institute Delaware Valley Pain & Spine Institute Western Reserve Hospital, Cuyahoga I Western Reserve Morges, Morges, Swi	itzerland:	
 Western Reserve Hospital, Cuyahoga Western Reserve Hospital, Cuyahoga Hopital de Zone Morges, Morges, Swi Hopital de Zone Morges, University Hospital 	pitals FH1, Essex, end	
 Western Reserve Hospital, Gurges, Swi Mopital de Zone Morges, Morges, Swi Basildon and Thurrock University Hos Robo Clinic, Newcastle, NSW, 	Australia	
*** Hunter Pan Clinical Research, Nap		
11 Basildon and Minic, Newcastle, NSW, *** Hunter Pain Clinic, Newcastle, NSW, th Neurovations Clinical Research, Nap th Doleys Clinic, Birmingham, AL, USA the Doleys Clinic, Birmingham, AL, USA Sector States, Clinics, Park, PA, USA	A USA:	
++ Doleys Clinc, Merticine Center, Lo	s Angelan -	
 California Pain Medicine Control MossRehab, Elkins Park, PA, USA; MossRehab, Elkins Park, PA, USA; The Johns Hopkins Hospital, Balti Hopkins, Hospital, Bryn Mawr, F 	MD. USA;	
11 Mossherado, Hopkins Hospital, Batt	na lisa	
**** The Johns Hopkins Hospital, Ball **** Biyn Mawr Hospital, Bryn Mawr, F Hyn Mawr Hospital, Newark, DE, I		
++++ Bryn Mawr Hospital, Bryn Maw, ++++ Christiana Hospital, Newark, DE, I ++++ Christiana Hospital, Newark, DE, I	Mashville, TN, USA	to http://www.wiley.
tttt Blyn Mawr Hospital, Newark, DE, I ttt Christiana Hospital, Newark, DE, I stat Vanderbilt University Medical Ce stat Vanderbilt University Medical Ce stat Pacific Pain Treatment Center (re stat Clinic, Evidence Base	et L San Francisco, CA, USA, and Cleveland, OH, USA	to med consent policies, please go to trop
and Pacific Pain Treatment Center the	ed Pain Management Kese and conflict of interest	Informed the
Cleveland Clinic, Evidence und	to a stice of our peer review process, and	The station M. Hayek"
abor mit	LEAR weight the Transformer, CA, LEAR and CH has Transformer, CA, LEAR and CH has Transformer, CA, LEAR and dealers, an explanation of our peer nerview process, and condition of interest dealers, an explanation of our peer nerview process, and condition of interest and the transformer performance of the second authors have been any top terminational Neurophysical Society and the transmissional Neurophysical Society and the terminational Neurophysical Society and the termination of termination of the termination of termination	from "Salim Hayek" to Salarit
For more information on autors 9	aml author has been	correction man
com/WileyCDA/Section/Id-Softas	the orbligation: the name of the second	Neuromodulation 2017; 20: 133-154
to tabulary 20	17, after first on the past	Neuromodos
(Correction added on 19 January	vie and Neuromodulation Society	
	© 2017 International Neuromodulation Society	
adulation journal.c	iom.	
www.neuromodulationjournal.c		

Painweek

PACC, Polyanalgesic Consensus Conference. Deer TR, et al. Neuromodulation. 2017;20(2):96-132; Deer TR, et al. Neuromodulation. 2017;20(2):133-154; Deer TR, et al. Neuromodulation. 2017;20(2):155-176

Intraspinal baclofen and multiple sclerosis

- Intraspinal baclofen is considered for people with severe spasticity unresponsive to oral baclofen or other less invasive approaches to spasticity management
- In one study, spasticity management using intraspinal baclofen was associated with reduced spasticity as well as reduced pain for at least 76 months
- What about those instances in which baclofen alone is not effective enough?

Stampacchia G, Gerini A, Mazzoleni S. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patinets: Long term follow-up. NeuroRehabilitation 2016 Apr6;38(4): 385-393.



Intraspinal Combination Therapy for Spasticity and Neuropathic Pain

- Clinical and preclinical studies support the use of ziconotide in combination with morphine, hydromorphone, clonidine or baclofen BUT no long term trials exist
- Specifically, in a case series, 7 patients experiencing both spasticity as well as neuropathic pain were treated with a combination of intraspinal baclofen and ziconotide- each person reported was treated with a different titration schedule and with different concentrations of each medication



Additional Treatments to Consider

- Physical therapy and exercise: aerobic exercise, respiratory muscle training, resistance training, stretching, stability training
- Neuromodulation: IT baclofen for spasticity control, Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), and Transcranial Magnetic Stimulation have been utilized
- DBS may help MS related tremor and TN
- SCS has been used to treat bladder dysfunction and MS related pain

Urits I, et al. Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review. Current Pain and Headache Reports(2019) 23:59, PMID 31342191.



Nonpharmacologic Treatment Modalities





CAM, complementary and alternative medicine; TENS, transcutaneous electrical nerve stimulation. Adams ML. *Clin Podiatr Med Surg*. 2008;25:409-429; Bruckenthal P. *Pain Manag Nurs*. 2010;11:S23-S31.

Cannabinoids

- Neurotransmission via the endocannabinoid pathway is increasingly appreciated to regulate pain perception and modulation
- CB1 receptor plays an important role; analgesics effects are lost when CB1 antagonist (rimonabant) is given
- Both enandamide and NADA (N-arachidonyldopamine) activate the vanilloid receptor (TRPV-1) found on sensory nerves
- May promote analgesia through CB1 and CB2, but potentially increase pain via TRPV-1
- Progress is being made in the development of novel agonists and antagonists with receptor subtype selectivity which should help in providing a greater understanding of the physiological role of the endocannabinoid system and perhaps also in a broad number of pathologies.

Painweek, Svízenská I, et al. Pharmacol Biochem Behav. 2008;90:501-511.

MS- Oral Cannabinoids (Cannabis extract and THC)


- Neither oral cannabis extract (OCE) nor dronabinol had a greater effect in MS patients in reducing spasticity as measured by the Ashworth scale compared to placebo- this was the primary outcome measure of this study.
- HOWEVER: for certain secondary outcome measures in this study, including pain associated with spasticity, muscle spasms and sleep both treatment groups demonstrated greater improvement than placebo treated patients

Yadev, V, Bever C, Bowen C, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis Neurology 2014;82:1083-1092



MS- Oral Cannabinoids (Cannabis extract and THC)-2

- In a randomized controlled study (RTC) of 249 MS patients treated with OCE, muscle stiffness was more likely to occur in treated pts compared with placebo (29.4% vs. 15.7%) and secondary outcomes including spasms, pain and sleep were more likely to occur in the treated group
- Another RTC showed no difference in Ashworth scale scores OR subjective symptoms in each group
- A RTC assessing the effect of OCE for tremor and bladder symptoms in MS patients did not show a significant difference between pts treated with cannabinoids and placebo



MS- Oral Cannabinoids (Cannabis extract and THC)-3


- Based upon these findings the American Academy of Neurology (AAN) advises:
- 1. OCE is established as *effective* for reducing patient-reported spasticity symptoms and pain
- 2. THC is *probably effective* for reducing patient-reported symptoms of spasticity and pain
- 3. OCE and THC are *probably ineffective* for reducing objective spasticity measures and tremors

Yadev, V, Bever C, Bowen C, et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis Neurology 2014;82:1083-




MS- Oromucosal Cannabinoid Spray

- A 6 week RTC including 160 MS pts evaluated the effect of the oromucosal cannabinoid spray (OCS) on spasticity: no objective measured difference was seen between groups
- A 5 week RTC in 66 pts with MS related central neuropathic pain demonstrated that the OCS was superior in reducing mean pain intensity compared to placebo
- A 10 week RTC in 135 pts with MS related urinary incontinence did not show improvement with OCS; HOWEVER, the daily # of voids did decrease significantly in the treatment group



MS- oromucosal Cannabinoid Spray-2

- Based upon these findings the American Academy of Neurology (AAN) advises:
- 1. OCS is *probably effective* for improving subjectuve spasticity symptoms, pain and urinary frequency
- 2. OCS is *probably ineffective* for reducing objective spasticity measures or bladder incontinence
- 3. OCS is *possibly ineffective* for reducing MS-related tremor



MS-Smoked Ccannabis

- I crossover study in 37 MS patients reported spasticity reduction- the primary outcome measure (using a modified Ashworth scale) in the cannabis group
- Pain, a secondary measure, also improved in the cannabis group
- Cognitive performance was measured and was REDUCED after cannabis treatment



MS-Smoked Cannabis-2

In a separate study of 20 MS pts and normal controls, both groups demonstrated reduced measures of posture and balance after smoking one marijuana cigarette.



MS-Smoked Cannabis-3

- Based upon these findings the American Academy of Neurology (AAN) advises:
- 1. **Data are not adequate** to determine the safety or efficacy of smoked cannabis used for spasticity or pain relief.



MS – Additional Thoughts

- The reported studies were of short duration- longest 15 weeks
- Central side effects of the active agent could have unmasked subject
- The Ashworth scale may be insensitive to spasticity changes in these studies
- The cannabinoids were associated with serious adverse events including death- mild-moderate side effects were more common (50-80%) including dizziness, lightheadness, increased appetite, nausea, emesis, cystitis, dehydration, transient psychosis, hallucinations and cognitive impairment



Randomized Controlled Trials of Smoked Cannabis in Pain

N=	Indication	Duration/type	Outcome
50	HIV neuropathy	5 days/DB	Decreased pain and hyperalgesia (Abrams, 2007)
23	Neuropathic pain	5 days/DB	Decreased pain (Ware, 2010)
38	Neuropathic pain	Single dose/DBC	Decreased pain w/ highest dose, but significant psychoactive effects (Wilsey, 2008)
34	HIV neuropathy	5 days/DB	Improved DDS, (Ellis, 2009)
21	Chronic pain on opioids	5 days/DB	27% decrease in pain (Abrams, 117)



Randomized Controlled Trials of Synthetic Cannabinoids in Pain

Agent	N=	Indication	Duration/type	Outcome
Ajulemic acid	21	Neuropathic pain	7 day crossover	Decreased pain (Karst, 2003)
Marinol	24	Neuropathic pain in MS	15-21 days/DBC	Median numerical pain and relief improved (Svendsen, 2004)
Marinol	40	Postop pain	Single dose/DB	No Benefit (Buggy, 2003)
Marinol	30	Chronic pain	3 doses, 1 day/DB	Total pain relief improved with 10 and 20 mg. AEs prominent, (Narang, 2008)



Randomized Controlled Trials of Synthetic Cannabinoids in Pain: Nabilone

Pa

N=	Indication	Duration/Type	Outcome
41	Postop pain	3 doses/24h, DB	No Benefit
31	Fibromyalgia	2 weeks/DBC	Compared to amitriptyline, sleep/wakefulness improved, no effect on pain, (Ware, 2010)
96	Neuropathic pain	14 weeks/DBC vs dihydrocodeine	DHC more effective with fewer AE (Frank, 2008)
13	Spasticity pain	9 weeks/DBC	Decreased pain, (Wissel, 2006)
40	Fibromyalgia	4 weeks/DBC	Decreased pain, FIQ, anxiety, (Skrabek, 2008)

Randomized Controlled Trials of Cannibis-Based Medicine in Pain: Sativex

N=	Indication	Duration/Type	Outcomes
20	Neurogenic pain	Series of 2 wk N of 1 crossover blocks (CB)	Decreased pain, (Wade, 2004)
24	Chronic pain	12 wks, series of N of 1 CB	Decreased pain in MS, (Notcutt, 2004)
48	Brachial Plex Avul	6 wks in 3 two- week CB	Decreased pain, (Berman, 133)
66	Central neuropathic pain of MS	5 weeks	Decreased pain, (Rog, 2005)
125	Peripheral neuropathic pain	5 weeks	Decreased pain and allodynia, (Nurmikko, 135)

Pa

Randomized Controlled Trials of Cannibis-Based Medicine in Pain: Sativex

N=	Indication	Duration/Type	Outcomes
56	Rheumatoid Arthritis	Nocturnal dosing for 5 weeks	Decreased pain and improved SF-MPQ, (Blake, 137)
117	Spinal cord injury pain	10 days	No effect on pain, improved BPI, PGIC, (unpublished)
117	Cancer Pain	2 weeks	Decreased pain, (Johnson, 138)
135	Lower urinary tract symptoms in MS	8 weeks	Improved symptoms, (Kavia, 2010)
360	Cancer Pain	5 weeks/DB	Decreased pain in low and middle dose, (Portenoy, 2012)



Randomized Controlled Trials of Cannabis-Based Medicines in Pain

Agent	N=	Indication	Duration/type	Outcome
Cannador	65	PHN	4 weeks	No benefit (Ernst, 2005)
Cannador	419	Pain in MS	15 weeks	Decreased pain associated with spasm (Zajicek, 2003)
Cannador	30	Postop pain	Single dose	Decreased pain with increase dose (Holdcroft, 2006)



Conclusions: Pain in Demyelinating Disease

- Pain is common in MS and other demyelinating conditions
- Multiple treatments are available BUT very little primary as well as comparative literature
- No treatment works for most patients
- Some medications aren't appropriate for some patients
- Some patients only want procedures
- Some patients only want medications
- Some patients want alternative approaches
- Bottom line: care must be individualized and more data is needed!

Painweek.

Post-test question #1

- A 30 year old female with a 10 year personal as well as family history of migraine headaches presents to her primary care provider for an annual health assessment. She describes having episodes of severe, sudden shock-like pain over the right mandible lasting seconds to minutes. She often cannot brush her teeth without pain. Her dentist has evaluated her recently and no dental etiology has been determined. Here PCP notes several trigger zones over the affected area when examining her. What is the most appropriate step for this patient?
- A. PCP should advise the patient that her complaints and findings are consistent with migraine and discuss new treatments for her headaches.
- B. PCP should advise the patient that her complaints are consistent with trigeminal neuralgia and she should be referred to a Neurosurgeon for consideration of microvascular decompression surgery.
- C. PCP should advise the patient that her complaints are consistent with trigemeinal neuralgia and she is advised to undergo a MRI Brain with and without contrast.
- D. PCP should advise the patient that her complaints are consistent with temporomandibular joint dysfunction and she is advised to see a TMJ specialist.

Painweek.

Post-test question #2

 T/F: 20% of people diagnosed with multiple sclerosis experience associated chronic pain.



Post-test question #3

T/F: A recent study suggests that most pain associated with multiple sclerosis is neuropathic pain.

